COMPANY:

PanGia Biotech

"PanGIA Biotech...today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA^® Liquid Biopsy Platform...Additional cancer types in the PanGIA follow-on study will include breast, ovarian, lung, renal, bladder, colorectal, stomach, pancreas, liver, and brain. The company will begin recruiting experienced medical professionals across the United States as clinical study sites as well as listing the study on ClinicalTrials.gov....PanGIA Biotech intends to launch the expanded study in mid-2024. Interested researchers may contact the company for additional information."